What is InnoCare Pharma Limited (INCPF)?

InnoCare Pharma Limited (INCPF) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of INCPF?

The current price of INCPF is $1.60. Prices are updated in real time on Stocks360.

What is INCPF's price-to-earnings (PE) ratio?

INCPF's trailing twelve-month PE ratio is 12.38, based on current price and earnings per share data available on Stocks360.

What is INCPF's market capitalization?

INCPF's market capitalization is $2,390,077,176.00, placing it in the mid-cap tier.

InnoCare Pharma Limited (INCPF)

Stock analysis · OTC · Healthcare · Biotechnology

$1.60

Market Cap

$2.39B

PE (TTM)

12.38

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.39

Day Range

$1.60 – $1.60

52-wk Range

$1.55 – $3.26

Avg Volume

N/A

Volume

200.00

InnoCare Pharma Limited (INCPF) is a publicly traded company in the Healthcare sector. Latest price: $1.60. Market cap $2.39B. Trailing PE 12.38. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 5 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-30 · $3.26 2026-10-26 · $1.60 (-50.92%)

Earnings

Most Recent

Oct 26, 2026

EPS $0.04 vs est. $-0.04

Beat by $0.07

Next Earnings

Apr 1, 2027

EPS estimate $-0.03

Proprietary Signals

Signal snapshot temporarily unavailable.

About InnoCare Pharma Limited

InnoCare Pharma Limited is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments, primarily targeting cancer and autoimmune disorders. A key product in their portfolio is Orelabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor. This therapy targets various relapsed or refractory blood cancers, including chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom's macroglobulinemia, marginal zone lymphoma, diffuse large B-cell lymphoma (MCD subtype), central nervous system lymphoma, and is also being explored in combination with MIL-62. Furthermore, Orelabrutinib is under investigation for a range of autoimmune conditions such as systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company's broader pipeline features several investigational candidates in various clinical trial stages. For example, ICP-192, a pan-FGFR inhibitor, is currently in Phase I/II trials for solid tumors like cholangiocarcinoma and head and neck cancer. Compounds in Phase I clinical trials include ICP-723, a pan-TRK inhibitor addressing cancers with neurotrophic t…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	12.38×
P/S (TTM)	4.27×
P/B	2.05×
PEG	0.01×
P/FCF (TTM)	43.39×
EV / EBITDA	8.24×
EV / Sales	3.15×
Earnings Yield	8.03%
Free Cash Flow Yield	2.30%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$10.49B
Revenue (TTM)	$3.33B
Net Income (TTM)	$1.14B
Free Cash Flow (TTM)	$382.90M
Net Debt	-$3.73B
Working Capital	$6.88B
Gross Margin	91.09%
Operating Margin	37.27%
Net Margin	40.53%
Return on Equity	17.47%
Return on Invested Capital	11.47%